Myocardial reperfusion injury: looking beyond primary PCI
- PMID: 23536610
- DOI: 10.1093/eurheartj/eht090
Myocardial reperfusion injury: looking beyond primary PCI
Abstract
Coronary heart disease (CHD) is the leading cause of death and disability in Europe. For patients presenting with an acute ST-segment elevation myocardial infarction (STEMI), timely myocardial reperfusion using either thrombolytic therapy or primary percutaneous coronary intervention (PPCI) is the most effective therapy for limiting myocardial infarct (MI) size, preserving left-ventricular systolic function and reducing the onset of heart failure. Despite this, the morbidity and mortality of STEMI patients remain significant, and novel therapeutic interventions are required to improve clinical outcomes in this patient group. Paradoxically, the process of myocardial reperfusion can itself induce cardiomyocyte death-a phenomenon which has been termed 'myocardial reperfusion injury' (RI), the irreversible consequences of which include microvascular obstruction and myocardial infarction. Unfortunately, there is currently no effective therapy for preventing myocardial RI in STEMI patients making it an important residual target for cardioprotection. Previous attempts to translate cardioprotective therapies (antioxidants, calcium-channel blockers, and anti-inflammatory agents) for reducing RI into the clinic, have been unsuccessful. An improved understanding of the pathophysiological mechanisms underlying RI has resulted in the identification of several promising mechanical (ischaemic post-conditioning, remote ischaemic pre-conditioning, therapeutic hypothermia, and hyperoxaemia), and pharmacological (atrial natriuretic peptide, cyclosporin-A, and exenatide) therapeutic strategies, for preventing myocardial RI, many of which have shown promise in initial proof-of-principle clinical studies. In this article, we review the pathophysiology underlying myocardial RI, and highlight the potential therapeutic interventions which may be used in the future to prevent RI and improve clinical outcomes in patients with CHD.
Keywords: Cardioprotection; Myocardial reperfusion injury; Primary percutaneous coronary intervention; ST-elevation myocardial infarction.
Similar articles
-
Mechanistic Role of mPTP in Ischemia-Reperfusion Injury.Adv Exp Med Biol. 2017;982:169-189. doi: 10.1007/978-3-319-55330-6_9. Adv Exp Med Biol. 2017. PMID: 28551787 Review.
-
The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.Eur Heart J. 2017 Mar 14;38(11):774-784. doi: 10.1093/eurheartj/ehw224. Eur Heart J. 2017. PMID: 27354052 Review.
-
Reducing myocardial infarct size: challenges and future opportunities.Heart. 2016 Mar;102(5):341-8. doi: 10.1136/heartjnl-2015-307855. Epub 2015 Dec 16. Heart. 2016. PMID: 26674987 Free PMC article. Review.
-
Conditioning the heart to prevent myocardial reperfusion injury during PPCI.Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):13-32. doi: 10.1177/2048872612438805. Eur Heart J Acute Cardiovasc Care. 2012. PMID: 24062884 Free PMC article.
-
Treatment of myocardial ischaemia-reperfusion injury in patients with ST-segment elevation myocardial infarction: promise, disappointment, and hope.Rev Cardiovasc Med. 2022 Jan 17;23(1):23. doi: 10.31083/j.rcm2301023. Rev Cardiovasc Med. 2022. PMID: 35092215 Review.
Cited by
-
Delivery of Hydrogen Sulfide by Ultrasound Targeted Microbubble Destruction Attenuates Myocardial Ischemia-reperfusion Injury.Sci Rep. 2016 Jul 29;6:30643. doi: 10.1038/srep30643. Sci Rep. 2016. PMID: 27469291 Free PMC article.
-
MicroRNA-223-5p and -3p Cooperatively Suppress Necroptosis in Ischemic/Reperfused Hearts.J Biol Chem. 2016 Sep 16;291(38):20247-59. doi: 10.1074/jbc.M116.732735. Epub 2016 Aug 8. J Biol Chem. 2016. PMID: 27502281 Free PMC article.
-
The Role of Mitochondrial Reactive Oxygen Species in Cardiovascular Injury and Protective Strategies.Oxid Med Cell Longev. 2016;2016:8254942. doi: 10.1155/2016/8254942. Epub 2016 Apr 21. Oxid Med Cell Longev. 2016. PMID: 27200148 Free PMC article. Review.
-
Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders.Curr Cardiol Rev. 2023;19(4):e090223213539. doi: 10.2174/1573403X19666230209111854. Curr Cardiol Rev. 2023. PMID: 36757031 Free PMC article.
-
Immune cells drive new immunomodulatory therapies for myocardial infarction: From basic to clinical translation.Front Immunol. 2023 Jan 24;14:1097295. doi: 10.3389/fimmu.2023.1097295. eCollection 2023. Front Immunol. 2023. PMID: 36761726 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous